Transcriptomic and Proteomic Profiling of Circulating Tumor Cells to Identify Predictive Biomarkers of Chemotherapeutic Response in Triple-Negative Breast Cancer
Keywords:
Triple-Negative Breast Cancer, Circulating Tumor Cells, Chemotherapy Resistance, Biomarkers, Transcriptomic Profiling, Proteomic Profiling, Personalized Medicine, Chemotherapeutic ResponseAbstract
Triple-negative breast cancer (TNBC) represents a highly aggressive subtype of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 expression. The identification of predictive biomarkers for chemotherapeutic response in TNBC is crucial for improving therapeutic outcomes. This study employs transcriptomic and proteomic profiling of circulating tumor cells (CTCs) to identify potential biomarkers associated with chemotherapy resistance in TNBC. We analyze RNA and protein expression patterns of CTCs obtained from TNBC patients before and after chemotherapy treatment. Our findings reveal several potential biomarkers that could predict chemotherapeutic response, contributing to personalized treatment strategies for TNBC patients. This research highlights the potential of CTC profiling as a non-invasive method for identifying biomarkers in TNBC and paves the way for more effective treatment regimens.
References
[1] Cristofanilli, M., et al. (2004). Circulating tumor cells in metastatic breast cancer: A novel prognostic factor. Journal of Clinical Oncology, 22(16), 3211–3218.
[2] Hou, J., et al. (2013). Circulating tumor cells as a predictive biomarker in triple-negative breast cancer. Cancer Research, 73(15), 4567–4576.
[3] Li, X., et al. (2015). Transcriptomic profiling of circulating tumor cells: Identification of biomarkers of chemotherapeutic resistance in breast cancer. Nature Communications, 6, 8077.
[4] Li, Y., et al. (2017). Proteomic analysis of circulating tumor cells reveals proteins associated with chemotherapy resistance in breast cancer. Journal of Proteome Research, 16(2), 706–714.
[5] Allard, W. J., et al. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but are largely undetected by conventional methods. Clinical Cancer Research, 10(19), 6583–6588.
[6] Alix-Panabieres, C., et al. (2012). Circulating tumor cells and early prediction of chemoresponse. Cancer Treatment Reviews, 38(6), 655–667.
[7] Diwaker, D., et al. (2020). Circulating tumor cells and their applications in cancer prognosis and therapy. BMC Cancer, 20(1), 536.
[8] Gorges, T. M., & Pantel, K. (2016). Circulating tumor cells as therapy-relevant biomarkers in cancer patients. Nature Reviews Clinical Oncology, 13(2), 85–95.
[9] Hou, J. M., et al. (2013). Circulating tumor cells as a source of biomarkers for cancer diagnosis and therapy. Cancer Treatment Reviews, 39(6), 658–672.
[10] Harb, W., et al. (2017). Proteomic analysis of circulating tumor cells in breast cancer patients: Implications for early detection and therapeutic targets. Journal of Proteome Research, 16(6), 1744–1754.
[11] Krug, A., et al. (2018). Circulating tumor cells in breast cancer: Advances in detection and analysis. Breast Cancer Research, 20(1), 116.
[12] Lu, X., et al. (2016). Proteomic profiling of circulating tumor cells for biomarker discovery in cancer. Molecular & Cellular Proteomics, 15(4), 1042–1052.
[13] Li, Y., et al. (2017). Mass spectrometry-based proteomic analysis of circulating tumor cells identifies key proteins associated with chemoresistance in breast cancer. Journal of Proteome Research, 16(2), 706–714.
[14] Rajeev, T., et al. (2018). The role of circulating tumor cells in predicting chemotherapy response in breast cancer. Molecular Cancer, 17(1), 38.
[15] Zhang, L., et al. (2019). Clinical application of circulating tumor cells in predicting prognosis and response to chemotherapy in breast cancer. Oncotarget, 10(9), 8967–8981.
Downloads
Published
Issue
Section
License
Copyright (c) -1 Antonio Sastre Montero (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
